Cumberland Pharmaceuticals has recently received approval from the US FDA for its RediTrex injection for the treatment of rheumatoid arthritis. Cumberland pharmaceuticals pharma company focusing on…
Category: The Business Cocktail
Sanofi’s Toujeo Okayed to treat Type 1,2 Diabetes; Hope for Alzheimer’s patients as TauRx shows positive results; Pfizer, Novartis along with others invest USD 2 Billion in Gene therapy
Sanofi’s Toujeo has received FDA recommendation for its expanded use in both Type 1 and Type 2 Diabetes. Toujeo is an insulin glargine injection to control…
Novartis buys Medicines Co. for USD 9.7 Billion; Alexion’s SOLIRIS receives approval in Japan for NMOSD; Ferring and Blackstone teams up to advance Bladder cancer gene therapy
Novartis plans to buy The Medicines Company for USD 9.7 Billion to gain access to a heart drug inclisiran, almost ready to get into the market….
GHO to advance healthcare in Europe; Truvian nets USD 27.1 Mn; Lilly plans its diabetes portfolio expansion
Global Healthcare Opportunities (GHO) Capital, a London-based healthcare investment firm, has recently netted USD 1.1 Billion to advance European healthcare. The company plans to use the…
Nordisk ties up with Dicerna; Pfizer’s drug gets FDA nod; Alkermes buys Rodin
Novo Nordisk has announced to enter into a collaboration with Dicerna’s RNAi platform to focus on metabolic and liver-related diseases. The companies will be focusing to…
Merck buys Calporta’s preclinical neurodegenerative assets; GSK’s Nucala targets rare inflammatory disease; AbbVie Sells bonds to Fund Allergan takeover
AbbVie has traded off its bonds worth USD 30 Billion to finance the purchase of the Allergan. AbbVie this year in June has agreed to…
FDA declines the approval of Lipocine’s testosterone drug; Novartis Sandoz to buy Aspen Pharmacare Japanese Unit; FDA approves first therapy to treat a rare blood disorder
The US FDA for the third time has refused to give approval to Lipocine’s oral testosterone drug, Tlando. The drug is an oral testosterone replacement therapy…
Evotec, Vifor Pharma collaborates to cure kidney diseases; AZ takes major steps to advance pharma and medicine R&D in China; Amneal licenses-in a Myasthenia Gravis drug from Kashiv BioSciences
Switzerland-based Vifor Pharma and Germany-based Evotech AG have collaborated for the development and discovery of new treatments for kidney diseases. The launch of a new 50:50…
AstraZeneca tops the first Pharma Invention Index; Amgen to buy 20.5% stake in a Chinese pharmaceutical, BeiGene; Ascentage, Henlius collaborates to develop a Combination therapy
Amgen has announced to purchase 20.5% of the stake in Chinese-American drug company BeiGene. As per the deal signed, Amgen will develop and commercialize around two…
AZ sells EU rights for Schizophrenia to Cheplapharm; Astellas, Pandion unite to extract the potential of immunomodulation; Pear therapeutics on a journey to develop digital GI treatments with Ironwood
AstraZeneca has announced the licensing-out of two of its drugs Seroquel and Seroquel XR in Europe and Russia to Cheplapharm Arzneimittel GmbH. According to the deal…